Egetis Therapeutics
Develops and commercializes treatments for serious and rare diseases.
EGTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0003815604
- LEI:
- 549300RZCKGWRUBPMY22
- Country:
- Sweden
- Address:
- Klara Norra Kyrkogata 26, 111 22 Stockholm
- Website:
- https://www.egetis.com/
- Sector:
- Manufacturing
Description
Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-02-17 08:00 | English | 414.1 KB | |||
| 2022-01-18 08:00 |
Egetis concludes that demonstrating treatment effects on T3 levels in MCT8-defi…
|
English | 130.0 KB | ||
| 2022-01-18 08:00 |
Egetis drar slutsatsen att en behandlingseffekt på T3-nivåer hos patienter med …
|
Swedish | 130.9 KB | ||
| 2021-12-13 08:00 |
Egetis planerar att lämna in ansökan om marknadsgodkännande för Emcitate® till …
|
Swedish | 109.4 KB | ||
| 2021-12-13 08:00 |
Egetis intends to submit a marketing authorisation application for Emcitate® to…
|
English | 122.1 KB | ||
| 2021-11-05 08:00 |
Valberedning utsedd inför årsstämman 2022 i Egetis Therapeutics
|
Swedish | 99.8 KB | ||
| 2021-11-05 08:00 |
Nomination Committee appointed for the 2022 Annual General Meeting in Egetis Th…
|
English | 79.2 KB | ||
| 2021-11-04 08:37 | Swedish | 395.7 KB | |||
| 2021-11-04 08:00 | English | 446.3 KB | |||
| 2021-09-14 10:53 | English | 33.9 KB | |||
| 2021-08-19 08:00 | Swedish | 382.2 KB | |||
| 2021-08-19 08:00 | English | 429.5 KB | |||
| 2021-05-24 11:00 |
Chairman of the board of directors in Egetis Therapeutics acquires shares
|
English | 96.4 KB | ||
| 2021-05-24 11:00 |
Styrelseordförande i Egetis Therapeutics förvärvar aktier
|
Swedish | 84.8 KB | ||
| 2021-05-17 14:00 |
CEO and senior executives in Egetis Therapeutics acquire shares
|
English | 97.7 KB |
Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Egetis Therapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-09 | Yilmaz Mahshid | Other | Sell | 39,753 | 268,332.75 SEK |
| 2025-01-08 | Yilmaz Mahshid | Other | Sell | 98,567 | 653,499.21 SEK |
| 2025-01-07 | Yilmaz Mahshid | Other | Sell | 74,769 | 507,681.51 SEK |
| 2024-10-07 | Nicklas Westerholm | Other | Buy | 10,142 | 43,103.50 SEK |
| 2024-10-07 | Yilmaz Mahshid | Other | Buy | 10,000 | 42,250.00 SEK |
| 2023-07-07 | Henrik Krook | Other | Buy | 33,594 | 133,704.12 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 3,616 | 14,391.68 SEK |
| 2023-07-06 | Christian Sonesson | Other | Buy | 2,000 | 7,920.00 SEK |
| 2023-07-05 | Christian Sonesson | Other | Buy | 1,384 | 5,452.96 SEK |
| 2023-07-04 | Nicklas Westerholm | Other | Buy | 15,350 | 60,632.50 SEK |
Peer Companies
